Corxel Pharmaceuticals closed a $287 million financing round to fund global development of its oral GLP‑1 candidate licensed from Vincentage. The financing will support phase 2/3 studies and commercial roll‑out plans as Corxel moves a China-originated oral GLP‑1 toward global registration. Company statements framed the capital as growth-stage support to compete with injectable GLP‑1s. Investor and press accounts highlighted Corxel’s strategy to position an oral GLP‑1 as a lower-cost, orally dosed alternative to injectables. Market observers will track forthcoming phase 2 data and how Corxel positions efficacy and safety against established injectables as it scales clinical programs and manufacturing.